In AD, new therapeutic targets have been explored that focus on the modulation of the cholinergic pathway by administration of acetylcholinesterases inhibitors, α7 nAChR agonists, and vagus nerve stimulation. Here, CHRNA7 is linked to Alzheimer disease.